Pharvaris (PHVS) Stock Price, News & Analysis

Company Overview

Pharvaris NV is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel therapies for rare, bradykinin‐mediated diseases. The company’s primary focus is hereditary angioedema (HAE), a genetic condition characterized by recurrent, debilitating swelling episodes. Pharvaris leverages a small‐molecule approach targeting the bradykinin B₂ receptor, aiming to provide both prophylactic and on‐demand treatment options that improve upon current injectable therapies.

The company’s lead product candidate, PHA121, is an oral, selective bradykinin B₂ receptor antagonist currently in Phase 1 clinical trials. Preclinical data have demonstrated favorable pharmacokinetics, strong receptor occupancy and a safety profile supporting further development. In addition to PHA121, Pharvaris is advancing a pipeline of next‐generation molecules designed to address unmet needs in HAE and potentially other bradykinin‐driven conditions, with plans to initiate additional clinical studies in the near term.

Founded in 2017 as a spin‐out from academic research, Pharvaris has grown rapidly to assemble a team experienced in rare disease drug development. The company’s scientific founders brought deep expertise in vascular biology and peptide chemistry, while its operational leaders have held senior roles at leading pharmaceutical firms and biotech companies. This blend of academic rigor and industry know‐how underpins Pharvaris’s approach to translating novel science into patient‐focused therapies.

Headquartered in Cambridge, Massachusetts, and with a research facility in Belgium, Pharvaris serves global markets and aims to address the needs of HAE patients in North America, Europe and beyond. The company is led by CEO Jonathan Bangs, whose prior experience includes leadership roles at both emerging biotech firms and large pharmaceutical organizations, and is supported by a board and management team with decades of combined expertise in drug discovery, clinical development and commercial strategy.

Key Stats

• Today's Range: $17.63 to $18.50
• 50-Day Range: $15.46 to $18.76
• 52-Week Range: $11.51 to $25.50
• Volume: 45,346 shs
• Average Volume: 70,396 shs
• Market Capitalization: $967.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.20
• Consensus Rating: Buy

Pharvaris Stock Analysis - MarketRank™

Pharvaris scored higher than 33% of companies evaluated by MarketBeat, and ranked 669th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pharvaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pharvaris has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pharvaris are expected to decrease in the coming year, from ($2.71) to ($3.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharvaris is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharvaris is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pharvaris has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.50% of the float of Pharvaris has been sold short.

Short Interest Ratio / Days to Cover

Pharvaris has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Pharvaris has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharvaris does not currently pay a dividend.

Dividend Growth

Pharvaris does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.50% of the float of Pharvaris has been sold short.

Short Interest Ratio / Days to Cover

Pharvaris has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Pharvaris has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.82

News Sentiment

Pharvaris has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Pharvaris this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharvaris insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.

PHVS Stock Analysis - Frequently Asked Questions

How have PHVS shares performed this year?

Pharvaris' stock was trading at $19.17 at the start of the year. Since then, PHVS shares have decreased by 3.5% and is now trading at $18.50.

How were Pharvaris' earnings last quarter?

Pharvaris N.V. (NASDAQ:PHVS) posted its earnings results on Tuesday, May, 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.09.

When did Pharvaris IPO?

Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

How do I buy shares of Pharvaris?

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pharvaris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHVS
• CIK: 1830487
• Web: www.pharvaris.com
• Phone: 31-71-203-6410
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pharvaris: $36.20
• High Price Target: $55.00
• Low Price Target: $25.00
• Potential Upside/Downside: +95.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$145.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.02%
• Return on Assets: -50.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.10
• Quick Ratio: 11.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.54 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 52,290,000
• Free Float: 46,099,000
• Market Cap: $967.37 million
• Optionable: Not Optionable
• Beta: -2.82